BTSR yields 200000000.00% · ABBV yields 3.06%● Live data
📍 BTSR pulled ahead of the other in Year 1
Combined, BTSR + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BTSR + ABBV for your $10,000?
BrightStar Information Technology Group, Inc. provides application engineering services to Global 2000 and midsized companies, and public sector organizations in the United States. It helps organizations in implementing and /or supporting enterprise-level packaged-systems applications and legacy software systems. The company primarily operates in two areas, Enterprise Resource Planning and Legacy Systems. In the Enterprise Resource Planning area, BrightStar implements and /or supports software from SAP, A.G., covering a range of business processes, including finance, human resources, and payroll. It also provides training and other consulting services related to Actuate software, which retrieves business information from corporate databases and delivers it as interactive Web pages and Excel spreadsheets. In the Legacy Systems area, it operates as a subcontractor and supports the fiscal intermediary standard system, which is used to process claims under Medicare Part A. In addition, BrightStar provides e-communication solutions and content management systems to clients in the not-for-profit sector, as well as software support and training services to various corporations. The company was founded in 1997 and is based in Pleasanton, California. BrightStar Information Technology Group, Inc. is a subsidiary of Stellar McKim LLC.
Full BTSR Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.